Terapia combinada temprana versus escalada gradual en diabetes tipo 2 recién diagnosticada: una revisión sistemática y metaanálisis de múltiples resultados clínicos

To evaluate efficacy, durability, and safety of early combination therapy compared with stepwise escalation in newly diagnosed type 2 diabetes.

We searched PubMed, Cochrane CENTRAL, and Embase through November 2025 for trials comparing early combination therapy with stepwise escalation in treatment-naïve patients. Outcomes included A1C reduction, time to treatment failure, beta cell function, hypoglycemia, weight change, cardiovascular risk markers, and hepatic outcomes. The random-effects meta-analysis used the inverse variance method.

Eleven studies (24,364 participants) were included. Early combination therapy achieved greater A1C reduction versus stepwise escalation (mean difference -0.49%, 95% CI: -0.53 to -0.45, p<0.001) and nearly doubled time to treatment failure (61.9 versus 36.1 months, HR 0.51, p<0.0001). Beta cell function was preserved for 3.5 years with early combination therapy, compared to a progressive decline with stepwise therapy. Early combination therapy demonstrated a 7.5-fold lower incidence of hypoglycemia, favorable effects on weight (5.3 kg difference), reduced carotid atherosclerosis progression, improved blood pressure and lipid profiles, and reduced hepatic fat accumulation.

Early combination therapy is superior to stepwise escalation in glycemic control, durability, beta-cell preservation, safety, and cardiovascular risk reduction, thereby supporting disease modification rather than merely symptomatic control.